> For Research Purposes Only. Thymosin alpha-1 (thymalfasin) is an approved immunomodulatory drug in a number of countries but is not FDA-approved in the United States for any indication. This article summarizes published scientific literature for educational and research purposes only. It is not medical advice and not a dosing protocol. Not for human use outside an approved clinical or regulatory setting.
Overview
Thymosin alpha-1 (Tα1), marketed internationally as thymalfasin under the trade name Zadaxin, is a 28-amino-acid acetylated peptide originally isolated from thymosin fraction 5, a partially purified extract of calf thymus. It is now produced synthetically. Of the compounds commonly discussed in the research-peptide space, Tα1 has by a wide margin the most substantial clinical evidence base: it has been evaluated in randomized controlled trials across sepsis, chronic hepatitis B and C, hepatocellular carcinoma, and viral respiratory infection, and it holds marketing approval in more than 30 countries.
Its regulatory position in the United States is the key nuance. Tα1 is not FDA-approved. It has held orphan drug designation for certain indications and has been studied under IND, but it has not received US marketing authorization. Descriptions of Tα1 as "an FDA-approved peptide" are incorrect and are a common error in secondary sources.
The compound's clinical story is also unusually instructive, because the largest and most rigorous trial conducted to date — a multicentre phase 3 study in sepsis published in The BMJ — did not confirm the benefit suggested by earlier smaller studies and meta-analyses.
Mechanism of Action
Thymosin alpha-1 is a thymic peptide whose principal described activity is immune modulation rather than immune stimulation in the crude sense. The distinction matters: the reported effects are context-dependent, with the peptide described as enhancing depressed immune function and moderating excessive inflammatory activation, rather than driving unidirectional immune activation.
The best-characterized mechanistic elements are:
T-cell maturation and function. Tα1 has been reported to promote maturation of T-lymphocyte precursors, increase circulating CD4+ and CD8+ populations in states of immune depletion, and enhance T-cell responsiveness. A foundational review, "Thymosin alpha 1: from bench to bedside," in the Annals of the New York Academy of Sciences consolidates the early mechanistic work (PMID: 17600290).
Toll-like receptor signaling. Tα1 has been described as engaging TLR-mediated pathways on dendritic cells and monocytes, influencing the balance of dendritic cell maturation and downstream Th1 polarization. This is the proposed bridge between innate signal reception and the adaptive T-cell effects.
Th1/Th2 balance. Clinical work in hepatitis B measured Tα1's effect on T-helper cytokine synthesis, reporting a shift in the Th1/Th2 profile in HBeAg-positive patients (PMID: 21227010). Th1 polarization is the mechanistically expected direction for an agent intended to restore antiviral cellular immunity.
Myeloid-derived suppressor cells. The picture is not uniformly "pro-immune." A study in Biochemical and Biophysical Research Communications reported that Tα1 promoted activation of myeloid-derived suppressor cells in a Lewis lung cancer model via upregulation of Arginase 1 (PMID: 26111447) — an immunosuppressive effect in a tumor context. This is an important counterweight to simplified accounts of the peptide and a genuine open question for oncology applications.
A comprehensive review of the literature covering mechanism and clinical application was published in the World Journal of Virology (PMID: 33362999).
Research Evidence
Sepsis. This is the most rigorously studied indication and the one where the evidence trajectory is most informative. Multiple systematic reviews and meta-analyses of earlier randomized trials — largely conducted in China and India — reported mortality benefit. A 2016 systematic review in BMC Infectious Diseases assessed Tα1 as immunomodulatory treatment for sepsis (PMID: 27633969); further meta-analyses examined Tα1 alone and in combination with ulinastatin (PMID: 26522590; PMID: 26517783; PMID: 27340674; PMID: 28069319).
Then came the definitive test. The TESTS trial — a multicentre, double-blinded, randomised, placebo-controlled phase 3 study — was published in The BMJ in 2025 (PMID: 39814420). A subsequent systematic review and meta-analysis of randomized controlled trials in Frontiers in Cellular and Infection Microbiology re-examined the pooled evidence in light of it (PMID: 40969554). Researchers evaluating this compound should read the phase 3 result as the primary evidence and treat the earlier meta-analyses as the hypothesis it was designed to test — not as independent confirmation of it. The pattern of promising small-trial meta-analyses followed by a large rigorous trial is one of the most common ways a therapeutic hypothesis is falsified.
Chronic hepatitis B. Tα1 has been studied both as monotherapy and, more productively, as an adjunct. A prospective multicenter randomized open-label study evaluated Tα1 combined with peginterferon α-2a versus peginterferon monotherapy in HBeAg-positive chronic hepatitis B (PMID: 22726105). A later prospective multicenter randomized open-label study examined entecavir plus Tα1 in HBV-related compensated cirrhosis (PMID: 30063860), and a systematic review and meta-analysis assessed entecavir plus Tα1 versus entecavir monotherapy in HBV-related cirrhosis (PMID: 33076834). A broader review of thymalfasin in hepatitis B and C appeared in the Annals of the New York Academy of Sciences (PMID: 20536462).
Hepatocellular carcinoma. A multicenter, randomized, observation-controlled clinical trial was designed to evaluate thymalfasin as adjuvant therapy in patients with HBV-related HCC following curative resection; the protocol announcement was published in Expert Opinion on Biological Therapy (PMID: 26094695).
COVID-19 and post-viral immune states. Tα1 was studied extensively during the pandemic with mixed results that illustrate the importance of endpoint selection. A study in Open Forum Infectious Diseases reported that Tα1 mitigated cytokine storm in blood cells from COVID-19 patients (PMID: 33506065). A retrospective cohort reported adjuvant use (PMID: 35728851), and work in International Immunopharmacology reported restoration of lymphocyte immune homeostasis in post-acute sequelae of SARS-CoV-2 infection (PMID: 36989892). Against these, a study in Frontiers in Immunology reported explicitly that Tα1 had no beneficial effect on restoring CD4+ and CD8+ T lymphocyte counts in COVID-19 patients (PMID: 34149679). A review in Immunity & Ageing surveyed Tα1 as an immunomodulator of the anti-SARS-CoV-2 response (PMID: 37408063), and work in Pneumonia examined thymalfasin in COVID-19 pneumonia recovery (PMID: 37743481).
Preclinical & Clinical Studies
The preclinical foundation dates to the isolation and characterization of thymosin fraction 5 and the subsequent identification of Tα1 as an active component. Early animal work established immune-restorative effects in thymectomized and immunosuppressed models, and Tα1 has been examined as a vaccine adjuvant in experimental settings, including work on thymosin alpha-1 and fusion proteins enhancing vaccination efficacy in an infectious-disease model (PMID: 7992547).
The clinical program is unusual for a peptide in this space in that it consists of genuine randomized trials with published protocols and prespecified endpoints, rather than case series. The indications where Tα1 has the most consistent supporting evidence are those involving documented immune depression — chronic viral hepatitis with impaired antiviral T-cell response, post-resection immune suppression, chemotherapy-associated lymphopenia. The indication where the strongest trial produced a null or non-confirmatory result is sepsis, a condition with far more heterogeneous immune pathophysiology.
That contrast is probably the most useful predictive heuristic in this literature: Tα1's reported effects are largest where a specific immune deficit is measurable and the intervention is targeted at restoring it, and smallest where "immune dysregulation" is a heterogeneous mix of hyperinflammation and immunoparalysis across a mixed patient population.
Safety Profile
Thymosin alpha-1 has an unusually favorable reported tolerability profile for a compound with this much clinical exposure. Across trials in hepatitis, sepsis, and oncology adjuvant settings, adverse events have generally been mild — injection-site reactions being the most commonly reported — with no consistent pattern of serious drug-attributed toxicity. Its approval in more than 30 countries reflects that record.
Important qualifications remain:
- •Not FDA-approved. US availability outside a clinical trial is not lawful pharmaceutical supply, and material obtained through research-chemical channels carries no identity, purity, or sterility guarantee.
- •Immunomodulation is bidirectional. The MDSC/Arginase-1 finding in a tumor model (PMID: 26111447) means the assumption that Tα1 is uniformly beneficial in cancer settings is not established. Context matters.
- •Autoimmune conditions. Modulating T-cell function in patients with active autoimmune disease has not been well characterized and is a plausible risk domain.
- •Combination context. Much of the positive clinical evidence comes from combination regimens (with peginterferon, entecavir, or ulinastatin). Efficacy in combination does not establish monotherapy efficacy.
Research Context
Thymosin alpha-1 deserves to be evaluated on a different standard than most compounds in the research-peptide space, because unlike them it has actually been tested. It has published phase 3 data, international regulatory approvals, and a mechanistic literature spanning four decades.
That same evidence base is why the honest summary is more measured than the marketing. The large sepsis trial did not confirm the benefit that smaller studies suggested. The hepatitis evidence is real but is largely adjunctive rather than standalone. The oncology signal is mixed and includes a plausible immunosuppressive mechanism. And the US regulatory position is that it remains unapproved.
The most productive open questions are patient-selection questions rather than yes/no efficacy questions: can a measurable immune-deficit biomarker (lymphocyte subset counts, HLA-DR expression on monocytes, T-cell functional assays) identify the subgroup in whom Tα1 produces benefit? A therapy that restores deficient immunity should be expected to work only in patients whose immunity is measurably deficient — and almost none of the trials to date have enrolled on that basis.
Disclaimer
For Research Purposes Only. This article is an educational summary of published scientific literature. Thymosin alpha-1 is not approved by the US Food and Drug Administration for the diagnosis, treatment, cure, or prevention of any disease. Regulatory status differs by jurisdiction. Nothing here is medical advice, a treatment recommendation, or a dosing protocol. Peptides.SO does not sell peptides and does not endorse the use of any research compound in humans. Individuals with health concerns should consult a licensed physician. Researchers should ensure all work complies with applicable institutional, national, and international regulations.